RNAC
Price
$10.64
Change
+$0.64 (+6.40%)
Updated
Sep 5 closing price
Capitalization
276.66M
XOMAP
Price
$26.76
Change
+$0.11 (+0.41%)
Updated
Sep 5 closing price
Capitalization
N/A
Interact to see
Advertisement

RNAC vs XOMAP

Header iconRNAC vs XOMAP Comparison
Open Charts RNAC vs XOMAPBanner chart's image
Cartesian Therapeutics
Price$10.64
Change+$0.64 (+6.40%)
Volume$24.44K
Capitalization276.66M
XOMA
Price$26.76
Change+$0.11 (+0.41%)
Volume$1.79K
CapitalizationN/A
RNAC vs XOMAP Comparison Chart in %
Loading...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RNAC vs. XOMAP commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RNAC is a Hold and XOMAP is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (RNAC: $10.64 vs. XOMAP: $26.76)
Brand notoriety: RNAC and XOMAP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RNAC: 41% vs. XOMAP: 120%
Market capitalization -- RNAC: $276.66M vs. XOMAP: $0
RNAC [@Biotechnology] is valued at $276.66M. XOMAP’s [@Biotechnology] market capitalization is $0. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RNAC’s FA Score shows that 0 FA rating(s) are green whileXOMAP’s FA Score has 1 green FA rating(s).

  • RNAC’s FA Score: 0 green, 5 red.
  • XOMAP’s FA Score: 1 green, 4 red.
According to our system of comparison, XOMAP is a better buy in the long-term than RNAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RNAC’s TA Score shows that 4 TA indicator(s) are bullish while XOMAP’s TA Score has 3 bullish TA indicator(s).

  • RNAC’s TA Score: 4 bullish, 5 bearish.
  • XOMAP’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, XOMAP is a better buy in the short-term than RNAC.

Price Growth

RNAC (@Biotechnology) experienced а +5.87% price change this week, while XOMAP (@Biotechnology) price change was +2.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XOMAP YTD gains are higher at: 10.119 vs. RNAC (-40.592). XOMAP has higher annual earnings (EBITDA): -305K vs. RNAC (-118.73M). RNAC has more cash in the bank: 160M vs. XOMAP (83.9M). RNAC has less debt than XOMAP: RNAC (13.3M) vs XOMAP (115M). XOMAP has higher revenues than RNAC: XOMAP (12.8M) vs RNAC (1.03M).
RNACXOMAPRNAC / XOMAP
Capitalization277MN/A-
EBITDA-118.73M-305K38,928%
Gain YTD-40.59210.119-401%
P/E Ratio1.98N/A-
Revenue1.03M12.8M8%
Total Cash160M83.9M191%
Total Debt13.3M115M12%
FUNDAMENTALS RATINGS
RNAC: Fundamental Ratings
RNAC
OUTLOOK RATING
1..100
53
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
88
P/E GROWTH RATING
1..100
40
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RNACXOMAP
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
6%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
15%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
27%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
36%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
25%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
26%
Advances
ODDS (%)
Bullish Trend 13 days ago
83%
Bullish Trend 13 days ago
22%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
6%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
9%
View a ticker or compare two or three
Interact to see
Advertisement
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LZAGY72.360.46
+0.64%
Lonza Group AG
ACNDF0.92N/A
+0.40%
Ascendas India Trust
PFBX19.84N/A
N/A
Peoples Financial Corp.
LEGIF85.41N/A
N/A
Leg Immobilien SE
CCUR2500.00N/A
N/A
CCUR Holdings, Inc.

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with NCNA. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then NCNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
+6.40%
NCNA - RNAC
92%
Closely correlated
+0.35%
NBY - RNAC
91%
Closely correlated
-11.61%
TAOX - RNAC
91%
Closely correlated
+6.91%
SNGX - RNAC
89%
Closely correlated
-5.92%
KPRX - RNAC
89%
Closely correlated
-1.83%
More

XOMAP and

Correlation & Price change

A.I.dvisor tells us that XOMAP and RNAC have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XOMAP and RNAC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XOMAP
1D Price
Change %
XOMAP100%
+0.41%
RNAC - XOMAP
29%
Poorly correlated
+6.40%
XOMAO - XOMAP
26%
Poorly correlated
-0.03%
VRDN - XOMAP
25%
Poorly correlated
+0.43%
AXSM - XOMAP
25%
Poorly correlated
+0.61%
RARE - XOMAP
23%
Poorly correlated
+1.73%
More